{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:20:41Z","timestamp":1791505241126,"version":"4.3.4"},"reference-count":34,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,2,10]]},"DOI":"10.1253\/circrep.cr-24-0152","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T22:12:12Z","timestamp":1737411132000},"page":"76-85","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic Value of Submaximal Cardiopulmonary Exercise Testing in Patients With Cardiac Amyloidosis"],"prefix":"10.1253","volume":"7","author":[{"given":"Robin","family":"Willixhofer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Ermolaev","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kronberger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Eslami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Vilsmeier","sequence":"additional","affiliation":[{"name":"Institute for Medical Statistics, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rettl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nitsche","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kammerlander","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kastner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Niederseer","sequence":"additional","affiliation":[{"name":"Hochgebirgsklinik Davos, Medicine Campus Davos"},{"name":"Christine K\u00fchne Center for Allergy Research and Education (CK-CARE), Medicine Campus Davos"},{"name":"Department of Cardiology, Center of Translational and Experimental Cardiology (CTEC), University Heart Center Zurich, University Hospital Zurich, University of Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Badr Eslam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Buxbaum JN, Dispenzieri A, Eisenberg DS, F\u00e4ndrich M, Merlini G, Saraiva MJM, et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. <i>Amyloid<\/i> 2022; 29: 213\u2013219.","DOI":"10.1080\/13506129.2022.2147636"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. <i>J Am Coll Cardiol<\/i> 2023; 81: 1076\u20131126.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. <i>Circulation<\/i> 2019; 140: 16\u201326.","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. <i>Eur Heart J<\/i> 2017; 39: 2799\u20132806.","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. <i>J Am Coll Cardiol<\/i> 2016; 68: 1014\u20131020.","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality in light chain cardiac amyloidosis with heart failure. <i>Sci Rep<\/i> 2019; 9: 8552.","DOI":"10.1038\/s41598-019-44912-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. <i>J Clin Oncol<\/i> 2004; 22: 3751\u20133757.","DOI":"10.1200\/JCO.2004.03.029"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. <i>Blood<\/i> 2019; 133: 215\u2013223.","DOI":"10.1182\/blood-2018-06-858951"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cantone A, Serenelli M, Sanguettoli F, Maio D, Fabbri G, Dal Passo B, et al. Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: A systematic review and meta-analysis. <i>ESC Heart Fail<\/i> 2023; 10: 2740\u20132744.","DOI":"10.1002\/ehf2.14406"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Binder C, Duca F, Stelzer PD, Nitsche C, Rettl R, Aschauer S, et al. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. <i>Eur Heart J Cardiovasc Imaging<\/i> 2019; 20: 512\u2013524.","DOI":"10.1093\/ehjci\/jey225"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Holt MF, Fl\u00f8 A, Ravnestad H, Bj\u00f8rn\u00f8 V, Gullestad L, Andreassen AK, et al. Invasive haemodynamics at rest and exercise in cardiac amyloidosis. <i>ESC Heart Fail<\/i> 2024; 11: 1263\u20131268.","DOI":"10.1002\/ehf2.14621"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mezzani A. Cardiopulmonary exercise testing: Basics of methodology and measurements. <i>Ann Am Thorac Soc<\/i> 2017; 14(Suppl 1): S3\u2013S11.","DOI":"10.1513\/AnnalsATS.201612-997FR"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Albouaini K, Egred M, Alahmar A, Wright DJ. Cardiopulmonary exercise testing and its application. <i>Postgrad Med J<\/i> 2007; 83: 675\u2013682.","DOI":"10.1136\/hrt.2007.121558"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. American Thoracic Society; American College of Chest Physicians. ATS\/ACCP statement on cardiopulmonary exercise testing. <i>Am J Respir Crit Care Med<\/i> 2003; 167: 211\u2013277.","DOI":"10.1164\/rccm.167.2.211"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chaumont M, Forton K, Gillet A, Tcheutchoua Nzokou D, Lamotte M. How does the method used to measure the VE\/VCO(2) slope affect its value?: A cross-sectional and retrospective cohort study. <i>Healthcare (Basel)<\/i> 2023; 11: 1292.","DOI":"10.3390\/healthcare11091292"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Malhotra R, Bakken K, D\u2019Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. <i>JACC Heart Fail<\/i> 2016; 4: 607\u2013616.","DOI":"10.1016\/j.jchf.2016.03.022"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nicol M, Deney A, Lairez O, Vergaro G, Emdin M, Carecci A, et al. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. <i>Eur J Heart Fail<\/i> 2021; 23: 231\u2013239.","DOI":"10.1002\/ejhf.2016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yunis A, Doros G, Luptak I, Connors LH, Sam F. Use of ventilatory efficiency slope as a marker for increased mortality in wild-type transthyretin cardiac amyloidosis. <i>Am J Cardiol<\/i> 2019; 124: 122\u2013130.","DOI":"10.1016\/j.amjcard.2019.03.035"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Willixhofer R, Rettl R, Kronberger C, Ermolaev N, Gregshammer B, Duca F, et al. Cardiopulmonary exercise testing in transthyretin amyloid cardiomyopathy patients: A long-term follow-up study. <i>J Cardiovasc Med (Hagerstown)<\/i> 2024; 25: 704\u2013712, doi:10.2459\/JCM.0000000000001636.","DOI":"10.2459\/JCM.0000000000001636"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Badr Eslam R, \u00d6zt\u00fcrk B, Rettl R, Capelle CDJ, Qin H, Binder C, et al. Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy. <i>Circ Heart Fail<\/i> 2022; 15: e008381.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008381"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society\/American Thoracic Society technical standard: Field walking tests in chronic respiratory disease. <i>Eur Respir J<\/i> 2014; 44: 1428\u20131446.","DOI":"10.1183\/09031936.00150314"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Agostoni P, Dumitrescu D. How to perform and report a cardiopulmonary exercise test in patients with chronic heart failure. <i>Int J Cardiol<\/i> 2019; 288: 107\u2013113.","DOI":"10.1016\/j.ijcard.2019.04.053"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ioannou A, Fumagalli C, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, et al. Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis. <i>J Am Coll Cardiol<\/i> 2024; 84: 43\u201358.","DOI":"10.1016\/j.jacc.2024.04.011"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Patel RK, Bandera F, Venneri L, Porcari A, Razvi Y, Ioannou A, et al. Cardiopulmonary exercise testing in evaluating transthyretin amyloidosis. <i>JAMA Cardiol<\/i> 2024; 9: 367\u2013376.","DOI":"10.1001\/jamacardio.2024.0022"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Willixhofer R, Contini M, Emdin M, Magr\u00ec D, Bonomi A, Salvioni E, et al. Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing: A multicentre study. <i>ESC Heart Fail<\/i> 2024, doi:10.1002\/ehf2.15147.","DOI":"10.1002\/ehf2.15147"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shibata A, Izumiya Y, Yoshida T, Tanihata A, Yamaguchi Y, Kitada R, et al. Elevation of end-tidal CO2 during exercise is attenuated in patients with cardiac amyloidosis. <i>Heart Vessels<\/i> 2024; 39: 340\u2013348.","DOI":"10.1007\/s00380-023-02342-w"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hashimoto T, Ikuta K, Yamamoto S, Yoshitake T, Suenaga T, Nakashima S, et al. Right ventricular to pulmonary artery uncoupling is associated with impaired exercise capacity in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2025; 89: 31\u201340.","DOI":"10.1253\/circj.CJ-24-0402"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Paolillo S, Pellegrino R, Salvioni E, Contini M, Iorio A, Bovis F, et al. Role of alveolar \u03b22-adrenergic receptors on lung fluid clearance and exercise ventilation in healthy humans. <i>PLoS One<\/i> 2013; 8: e61877.","DOI":"10.1371\/journal.pone.0061877"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Robertson HT, Pellegrino R, Pini D, Oreglia J, DeVita S, Brusasco V, et al. Exercise response after rapid intravenous infusion of saline in healthy humans. <i>J Appl Physiol (1985)<\/i> 2004; 97: 697\u2013703.","DOI":"10.1152\/japplphysiol.00108.2004"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Binder C, Duca F, Binder T, Rettl R, Dachs TM, Seirer B, et al. Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. <i>Clin Res Cardiol<\/i> 2021; 110: 532\u2013543.","DOI":"10.1007\/s00392-020-01698-7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Patel L, Segar MW, Keshvani N, Subramanian V, Pandey A, Chandra A. Association of beta-blocker use with exercise capacity in participants with heart failure with preserved ejection fraction: A post hoc analysis of the RELAX Trial. <i>Am J Cardiol<\/i> 2024; 216: 48\u201353.","DOI":"10.1016\/j.amjcard.2024.01.023"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mesquita ET, Jorge AJL, Souza CVJ, Andrade TR. Cardiac amyloidosis and its new clinical phenotype: Heart failure with preserved ejection fraction. <i>Arq Bras Cardiol<\/i> 2017; 109: 71\u201380.","DOI":"10.5935\/abc.20170079"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>New Engl J Med<\/i> 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ruzzolini M, Ambrosetti M. Cardiopulmonary exercise testing in cardiac rehabilitation: From the reporting form to structured exercise prescription: A proposal from the Italian alliance for cardiovascular rehabilitation and prevention (Itacare-P). <i>Int J Cardiol Cardiovasc Risk Prev<\/i> 2023; 18: 200191.","DOI":"10.1016\/j.ijcrp.2023.200191"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/2\/7_CR-24-0152\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T03:28:47Z","timestamp":1739590127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/2\/7_CR-24-0152\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-24-0152","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"CR-24-0152"}}